- Home
- PMCB vs IMRN Comparison
PMCB vs IMRN Comparison
Compare PMCB & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMCB
- IMRN
- Stock Information
- Founded
- PMCB 1996
- IMRN 1994
- Country
- PMCB United States
- IMRN Australia
- Employees
- PMCB N/A
- IMRN N/A
- Industry
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- PMCB Health Care
- IMRN Health Care
- Exchange
- PMCB Nasdaq
- IMRN Nasdaq
- Market Cap
- PMCB 15.8M
- IMRN 15.0M
- IPO Year
- PMCB N/A
- IMRN N/A
- Fundamental
- Price
- PMCB $1.76
- IMRN $2.25
- Analyst Decision
- PMCB
- IMRN Strong Buy
- Analyst Count
- PMCB 0
- IMRN 1
- Target Price
- PMCB N/A
- IMRN $5.00
- AVG Volume (30 Days)
- PMCB 35.7K
- IMRN 7.2K
- Earning Date
- PMCB 09-17-2024
- IMRN 10-22-2024
- Dividend Yield
- PMCB N/A
- IMRN N/A
- EPS Growth
- PMCB N/A
- IMRN N/A
- EPS
- PMCB 0.54
- IMRN N/A
- Revenue
- PMCB N/A
- IMRN $3,271,194.00
- Revenue This Year
- PMCB N/A
- IMRN N/A
- Revenue Next Year
- PMCB N/A
- IMRN N/A
- P/E Ratio
- PMCB $3.23
- IMRN N/A
- Revenue Growth
- PMCB N/A
- IMRN 171.67
- 52 Week Low
- PMCB $1.39
- IMRN $1.48
- 52 Week High
- PMCB $2.58
- IMRN $5.96
- Technical
- Relative Strength Index (RSI)
- PMCB 48.73
- IMRN 32.37
- Support Level
- PMCB $1.72
- IMRN $2.66
- Resistance Level
- PMCB $1.94
- IMRN $2.73
- Average True Range (ATR)
- PMCB 0.19
- IMRN 0.19
- MACD
- PMCB -0.01
- IMRN -0.06
- Stochastic Oscillator
- PMCB 28.57
- IMRN 24.04
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
About IMRN Immuron Limited
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.